FDA Approves Drug Combo for Aggressive Thyroid Cancer
MONDAY, May 7, 2018 -- Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat BRAF-positive anaplastic thyroid cancer.
Tafinlar (dabrafenib) and Mekinist (trametinib) combined have been...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Pharmaceuticals | Thyroid | Thyroid Cancer